NCT05842928 Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
| NCT ID | NCT05842928 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ludwig-Maximilians - University of Munich |
| Condition | Deprescriptions |
| Study Type | INTERVENTIONAL |
| Enrollment | 352 participants |
| Start Date | 2023-03-25 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 352 participants in total. It began in 2023-03-25 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER intervention) on reductions in the use of psychotropic, sedative and anticholinergic potentially inappropriate medication (PSA-PIM) compared to a control intervention. The PARTNER intervention comprises (1) education for health care professionals, (2) an interprofessional workshop and case conference, (3) a pharmacy visit with brown bag/medication review and patient empowerment, (4) GP practice visit with shared decision making. The control intervention only comprises a pharmacy visit with brown bag review.
Eligibility Criteria
Inclusion Criteria: * Aged 65 years or older * Patient is capable of giving consent * GP contact in the quarter prior to inclusion * Current use of ≥ 5 drugs, including ≥ 1 PSA-PIM (hypnotics, opioids, gabapentinoids, antipsychotics, antidepressants, anticholinergic urospasmolytics) with a treatment duration of ≥ 6 months * Willingness to select a regular pharmacy for the study period * Consent to data exchange between GP and community pharmacy Exclusion Criteria: * Terminal illness (life expectancy \< 6 months) * Current treatment of pain associated with cancer * Other serious physical illness or mental distress (e.g. bereavement) that makes participation in the study impossible (according to the GP's assessment) * Psychiatric illness or addiction that makes participation in the study impossible (according to the GP's assessment) * Unable to meet the requirements of the study (participation in telephone or written questionnaires, visits to the GP practice or community pharmacy, alone or with the help of caregivers for physical infirmity) * Current participation in research projects on medication safety or geriatric medicine
Contact & Investigator
Tobias Dreischulte, Prof. Dr.
PRINCIPAL INVESTIGATOR
Institute of General Practice and Family Medicine, University Hospital, LMU Munich, Munich, Germany
Frequently Asked Questions
Who can join the NCT05842928 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Deprescriptions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05842928 currently recruiting?
Yes, NCT05842928 is actively recruiting participants. Contact the research team at tobias.dreischulte@med.uni-muenchen.de for enrollment information.
Where is the NCT05842928 trial being conducted?
This trial is being conducted at Bielefeld, Germany, Munich, Germany, Witten, Germany.
Who is sponsoring the NCT05842928 clinical trial?
NCT05842928 is sponsored by Ludwig-Maximilians - University of Munich. The principal investigator is Tobias Dreischulte, Prof. Dr. at Institute of General Practice and Family Medicine, University Hospital, LMU Munich, Munich, Germany. The trial plans to enroll 352 participants.